Monday, July 23, 2018
 
 
Company News: Page (1) of 1 - 07/11/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Polsinelli's Seattle Expansion Capped by Two National Accolades in Health Care
 
(July 11, 2018)

KANSAS CITY, Mo., July 11, 2018 /PRNewswire/ -- Am Law 100 firm Polsinelli this month has earned top recognition for its Health Care Department by two prominent national organizations:  American Health Lawyers Association (AHLA) and Modern Healthcare.

Matt Murer, Polsinelli Health Care Department Chair

In May, Polsinelli opened its 21st office in Seattle with eight lawyers practicing in the areas of health care, government investigations, bankruptcy, and corporate and transactions. The firm's vibrant health care, real estate and intellectual property practices drove the firm to focus on expanding to the Pacific Northwest. These two most recent awards confirm Polsinelli's strategy to provide a comprehensive geographic network of attorneys in the health care area.



This month, the firm ranked No. 1 in AHLA's 2018 Top Honors report for the size of its membership within the organization. It is the nation's second-largest healthcare law firm, according to Modern Healthcare's 2018 Healthcare Law Firm Survey.

This is the ninth-consecutive year Polsinelli has earned a place on AHLA's Top 10 Firms list. The ranking is based on the current number of AHLA member attorneys at the firm: 284, which is nearly a nine percent increase over 2017.

Polsinelli has been highly-ranked by Modern Healthcare for six straight years on its "Largest Healthcare Law Firms" list, securing the No. 2 position in 2018 with more than 255 health care attorneys who practice in offices from coast to coast.

"We have worked hard to build a strong, national team of health care lawyers with experience that spans virtually every aspect of the health care continuum, as well as virtually every niche of practice," said Polsinelli Health Care Department Chair Matt Murer. "We're proud to be among the leading law firms in the country in health care law. These rankings recognize our team's commitment to strive for excellence each and every day, and our firm's pledge and investment to be a national leader in health care law."                                         

Earlier, Polsinelli received top recognition as the 2018 "Law Firm of the Year" in health care by U.S. News & World Report. As the firm's Health Care Department continues to expand and serve as a national leader in a full-range of health care law services, its diverse mix of attorneys provide counsel that aligns legal strategies with clients' unique and complex business objectives.

"Representing health care providers across the country requires depth and experience in all facets of health care," said Polsinelli Chairman and CEO Russ Welsh. "These recognitions affirm our capabilities across the nation. Under Matt's able leadership we will continue to serve as trusted counsel throughout the ever evolving health care industry."

One of the fastest-growing health care practices in the nation, Polsinelli's team includes former in-house counsel of national health care institutions, the Office of Inspector General (OIG), and former U.S. Attorneys and Assistant U.S. Attorneys with direct experience in health care fraud investigations.

Polsinelli's steady growth has contributed to its nationwide expansion, including the opening of the firm's 21st office in Seattle to accommodate growing demand in the Pacific Northwest, as well as the recent addition of several high-profile health care attorney hires in Dallas, Los Angeles, and Washington, D.C. offices, to name a few.

About Polsinelli

Polsinelli is an Am Law 100 firm with more than 825 attorneys in 21 cities coast to coast. Ranked #24 for Client Service Excellence1 and #10 for best client relationships2 among 650 U.S. law firms, Polsinelli is also named among the top 30 best-known firms in the nation3 for the second consecutive year. The firm's attorneys provide value through practical legal counsel infused with business insight, and focus on health care, financial services, real estate, intellectual property, mid-market corporate, labor and employment, and business litigation. www.polsinelli.com  

12018 BTI Client Service A Team Report
22017 BTI Industry Power Rankings
32018 BTI Brand Elite

CONTACT: Carrie Trent, [email protected]

Polsinelli is Ranked No. 17 in Client Service Excellence by BTI

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/polsinellis-seattle-expansion-capped-by-two-national-accolades-in-health-care-300679588.html

SOURCE Polsinelli

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:USA,Science,Medical,Business,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Sciatica Market Research Valued 18.9 Billion US$ by 2023: A Comprehensive Sciatica Market Growth by by type, by Drug Treatment and by End User
  • Medical Sensors Market to be Worth US$18.74 Billion by 2023, Says TMR
  • Vision Care Product Market To Witness Enhanced Growth Owing To Rising Occurrence Of Eye Disorders Till 2021 | Million Insights
  • Global Prosthetic Heart Valve Market Reaching at a CAGR of +12.70% by Geography, Deployment Model, Component, and Key players are Boston Scientific Cardiology, CryoLife, Inc., Abbott

    Cancer
  • CStone Pharmaceuticals Appoints Former Goldman Sachs Executive Richard Yeh as CFO
  • Immune Advisors Publishes Peer-Reviewed Study Demonstrating Efficacy of a Probiotic and Digestive Enzymes Supplement in Protecting Against Side Effects of Cancer Chemotherapy
  • CytRx Corporation Announces Expiration of Outstanding Warrants
  • HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
  • Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines